Maervoet Johan, Bergemann Rito
Access Consulting, Parexel International, Wavre, Belgium.
Access Consulting, Parexel International, Basel, Switzerland.
Value Health. 2025 Jul;28(7):1038-1045. doi: 10.1016/j.jval.2025.03.015. Epub 2025 Apr 11.
In the absence of an accepted local EQ-5D-5L tariff, the National Institute for Health and Care Excellence (NICE) requires EQ-5D-5L responses to be mapped to the long-standing EQ-5D-3L UK value set. Their 2022 Manual recommends using the mapping function recently developed by the NICE Decision Support Unit (DSU), instead of the van Hout Crosswalk that was previously endorsed. Our aim was to compare utility values derived using these 2 mapping methods and assess the potential impact on decision making.
For all 3125 unique EQ-5D-5L health states, utility values for both mapping functions were obtained and compared using numerical analysis and data visualization. Simulations in synthetic patient populations were conducted to evaluate the potential impact of the mapping functions on utility values derived from EQ-5D-5L clinical trial data.
For 1898 (61%) health states spread across the severity spectrum, the DSU mapping function generates a higher utility value than the van Hout Crosswalk. The mean difference was 0.062 (±0.139 SD), ranging from +0.619 to -0.198 for individual health states. The simulations suggest that mean utility values estimated with the DSU mapping function may lie higher than those obtained with the van Hout Crosswalk.
Not only the choice of EQ-5D instrument, but also the mapping approach can have an impact on utility values. The DSU mapping function may shift UK utility values further upward, potentially affecting NICE decision making. The use of various combinations of instruments, mapping functions, and tariffs may soon make it challenging to bring together historical 3L evidence and a growing body of 5L-based evidence.
在缺乏公认的本地EQ - 5D - 5L关税的情况下,英国国家卫生与临床优化研究所(NICE)要求将EQ - 5D - 5L的回答映射到长期使用的EQ - 5D - 3L英国价值集。其2022年手册建议使用NICE决策支持单位(DSU)最近开发的映射函数,而不是先前认可的范霍特交叉映射法。我们的目的是比较使用这两种映射方法得出的效用值,并评估对决策的潜在影响。
对于所有3125种独特的EQ - 5D - 5L健康状态,获取两种映射函数的效用值,并使用数值分析和数据可视化进行比较。在合成患者群体中进行模拟,以评估映射函数对从EQ - 5D - 5L临床试验数据得出的效用值的潜在影响。
在分布于严重程度范围的1898种(61%)健康状态中,DSU映射函数产生的效用值高于范霍特交叉映射法。平均差异为0.062(±0.139标准差),单个健康状态的差异范围从 +0.619到 -0.198。模拟表明,用DSU映射函数估计的平均效用值可能高于用范霍特交叉映射法获得的平均效用值。
不仅EQ - 5D工具的选择,而且映射方法都可能对效用值产生影响。DSU映射函数可能会使英国的效用值进一步上升,潜在地影响NICE的决策。使用工具、映射函数和关税的各种组合可能很快会使整合历史3L证据和越来越多的基于5L的证据变得具有挑战性。